Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 28, 2019
Distillery Therapeutics

TSPO agonist to treat Parkinson's disease

BioCentury | Mar 14, 2016
Emerging Company Profile

AMO's CNS ammunition

AMO is repurposing compounds to treat CNS deficits in fragile X and DM1
BioCentury | Jan 19, 2015
Company News

Trophos, Roche deal

BioCentury | Oct 7, 2013
Clinical News

TRO40303: Phase II ongoing

BioCentury | Jun 6, 2013
Distillery Therapeutics

Indication: Neurology

BioCentury | Nov 7, 2011
Clinical News

TRO40303: Phase II started

BioCentury | Mar 7, 2011
Clinical News

TRO40303: Phase I data

BioCentury | Oct 11, 2010
Clinical News

TRO40303: Phase I started

BioCentury | Jan 4, 2010
Clinical News

TLN-4601: Phase II discontinued

Items per page:
1 - 10 of 20